PBH

Prestige Consumer Healthcare Inc. (Prestige Brands Holdings, Inc.) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the three-month period ended June 30, 2010. Prestige Brands Holdings, Inc. is a holding company engaged in the marketing, sales, and distribution of over-the-counter healthcare, personal care, and household cleaning brands. The company operates through three segments: Over-the-Counter Healthcare, Household Cleaning, and Personal Care. As of August 1, 2010, there were 50,042,413 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 3.4% year-over-year, driven primarily by a 10.1% increase in the Over-the-Counter Healthcare segment (Clear Eyes, Compound W). This was partially offset by declines in Household Cleaning (-3.4%) and Personal Care (-21.6%) due to distribution losses and private label competition.
• Profitability: Operating income rose 15.1% to $21.3 million. Net income increased 15.4% to $9.6 million. The increase in net income was aided by a $1.2 million reduction in advertising and promotion expenses.
• Debt Reduction: The company significantly reduced its debt load. In April 2010, it redeemed the remaining $28.1 million of Senior Subordinated Notes. Total indebtedness decreased from $328.1 million at March 31, 2010, to $299.6 million at June 30, 2010.
• Discontinued Operations: The company recorded a loss of $10,000 from discontinued operations (shampoo brands sold in 2009), compared to income of $331,000 in the prior year.

Outlook, Risks, and Management Commentary

• Capital Structure: The company refinanced its debt in March 2010, issuing $150 million in 8.25% Senior Notes (due 2018) and a $150 million Senior Term Loan (due 2016). It maintains a $30 million revolving credit facility.
• Covenants: The company is in compliance with all financial covenants, including a leverage ratio of less than 4.30 to 1.0 and an interest coverage ratio greater than 2.75 to 1.0.
• Legal Proceedings: A subsidiary, Medtech Products Inc., is involved in a qui tam action filed by San Francisco Technology Inc. alleging false patent markings regarding Dermoplast products. The case was transferred to the Southern District of New York, and the company intends to vigorously defend against it.
• Risks: Key risks include dependence on a limited number of customers (one customer accounted for 23.3% of sales), concentration of sales in four major brands (66.3%), reliance on third-party manufacturers, and potential inventory obsolescence.
• Guidance: The filing does not provide specific numerical guidance for the full fiscal year 2011. Management notes that operating results for the quarter are not necessarily indicative of full-year results.

Investor Verification Checklist

• Debt Covenants: Verify continued compliance with the 4.30:1 leverage ratio and 2.75:1 interest coverage ratio given the high debt load relative to equity.
• Personal Care Segment: Monitor the Personal Care segment (specifically the Cutex brand) for continued revenue declines due to private label competition and distribution losses.
• Legal Exposure: Track the status of the San Francisco Technology Inc. litigation regarding false patent markings to assess potential financial impact.
• Customer Concentration: Assess the risk associated with the top customer representing 23.3% of sales and 20.8% of accounts receivable.
• Inventory Valuation: Review the allowance for obsolete inventory ($2.2 million) and product returns ($6.1 million) given the company's reliance on estimates for these critical accounting policies.